This site is intended for healthcare professionals
Drug news

RP-G28 success in Phase II trial fro lactose Intolerance

Read time: 1 mins
Last updated:17th Feb 2012
Published:17th Feb 2012
Source: Pharmawand
Ritter Pharma announced results of a Phase II trial for which showed RP-G28 improved digestive symptoms associated with Lactose Intolerance, including abdominal pain, and also reduced breath hydrogen production (a commonly used diagnostic test for lactose maldigestion). An abstract summarising the results is being presented orally at the annual international Digestive Disease Week (DDW) 2012 meeting in San Diego, California on 22 May 2012.RP-G28 has the potential to become the first prescription drug approved for treating the symptoms of lactose intolerance, which affects more than 80 million people in the United States and 4.3 billion people worldwide.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.